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Abstract
OBJECTIVE:Differently located tumors of the same origin may exhibit diverse responses to the same therapeutics. To
test this hypothesis, we compared the responses of rodent hepatic and subcutaneous engrafts of rhabdomyosarcoma-1
(R1) to a vascular disrupting agent Combretastatin A4 phosphate (CA4P).METHODS: TwelveWAG/Rij rats, each bearing
three R1 implanted in the right and left hepatic lobes and subcutaneously in the thoracic region, received CA4P intra-
venously at 5 mg/kg (n = 6) or solvent (n = 6). Therapeutic responses were compared interindividually and
intraindividually among tumors of different sites till 48 hours after injection using in vivoMRI, postmortem digital micro-
angiography, and histopathology. RESULTS: MRI revealed that the subcutaneous tumors (STs) significantly increased
in volume than hepatic tumors (HTs) 48 hours after CA4P (P < .05). Relative to vehicle controls and treated group at
baseline, necrosis ratio, apparent diffusion coefficient, and enhancement ratio changed slightly with the STs but sig-
nificantly with HTs (P < .05) after CA4P treatment. Vessel density derived from microangiography was significantly
lower in STs compared to HTs without CA4P treatment. CA4P treatment resulted in decreased vessel density in HTs,
while it did not affect vessel density in STs. MRI and microangiography outcomes were supported by histopathologic
findings. CONCLUSIONS: MRI and microangiography allowed quantitative comparison of therapeutic responses to
CA4P in rats with multifocal tumors. The discovered diverse effects of the same drug on tumors of the same origin
but different locations emphasize the presence of cancer heterogeneity and the importance of individualization of
drug delivery.
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Introduction
Cancer is a largely unpredictable phenomenon involving complex inter-
actions between various processes and factors in malignant cells and
their microenvironment. Such complexities may result in markedly
different responses to a given treatment. The tumor vasculature is an
attractive target for therapy, because most tumor cells rely on an intact
vascular supply for their survival and growth. Vascular disrupting agents
(VDAs) that specifically target the endothelia, pericytes, or specific
proteins derived from the tumoral endothelium represent a fundamen-
tally new cancer-targeting strategy. Upon systemic administration of
VDAs that destroy the abnormal irregularly structured tumoral vascu-
lature, cancer cells are deprived of blood, oxygen, and nutrient supply,
leading to intratumoral hemorrhagic necrosis [1–3].
Combretastatin A4 phosphate (CA4P) is a small molecular VDA
that has been most intensively studied in preclinical research and clin-
ical trials [4–7]. It is the water-soluble phosphate prodrug of Combre-
tastatin A4, which is originally extracted from South African willow
tree, Combretum caffrum [8,9]. Following intracellular uptake, CA4P
is in vivo dephosphorylated by nonspecific endogenous phosphatases
into the active form of Combretastatin A4, the latter then binds to the
colchicines-binding site in β-tubulin of microtubule [10]. Although
structurally similar to colchicines, CA4P binds to tubulin more rapidly
with greater affinity comparing to colchicines [10,11]. An immediate
vascular collapse can be induced following injection of CA4P at a dose
of one tenth the maximum tolerated dose in experimental tumors [12],
which consequently causes delay of tumor growth [8,13–16]. Extensive
central necrosis up to 90% of tumor mass occurs with a thin rim of
viable tumor tissue fed by peripheral normal vessels [17,18]. This re-
maining viable tissue is responsible for the rapid tumor regrowth after
a single administration found in preclinical models [19]. Therefore,
practically CA4P often has to combine with cytotoxic agents, radio-
therapy, and angiogenesis inhibitors to achieve enhanced tumor control
[20–24].
Proper understanding of tumor responses to CA4P may provide
new avenues for overcoming drug resistance and improving therapeu-
tic efficacy [25]. The susceptibility of different tumor types to CA4P
has been studied extensively [26–30]. However, previous studies on
CA4P were performed in animal models with tumor growing either
in one certain viscus [24,30,31] or in subcutaneous lacuna [32–34].
We hypothesized that tumors of the same nature but in different organs
may reveal different therapeutic responses to the same anticancer agent.
To the best of our knowledge, such an intraindividual comparison of
tumor responses to CA4P has never been experimentally investigated.
To verify our hypothesis, we developed a rat model of multifocal
tumors, i.e., two hepatic tumors (HTs) and one subcutaneous tumor
(ST), by surgical implantation of rhabdomyosarcoma-1 (R1) tissues.
Tumor responses to CA4P and vehicle were compared interindividually
and intraindividually among tumors in different sites using in vivo
magnetic resonance imaging (MRI) biomarkers and postmortem digital
microangiography and histopathology.
Materials and Methods
Tumor Models
This animal study was in compliance with national and European
regulations and approved by the Institutional Ethical Committee for
Animal Care and Use. Twelve male WAG/Rij rats weighting around
240 to 270 g received R1 tumors engrafted in the left and right hepatic
lobes and at subcutaneous thorax [20,35]. Briefly, animals underwent
midline laparotomy after being anesthetized with intraperitoneal in-
jection of pentobarbital (Nembutal; Sanofi Sante Animale, Brussels,
Belgium) at 50 mg/kg. Three freshly harvested R1 tissue cubes of
approximately 2 mm3 from a tumor-bearing donor rat were im-
planted into the left and right hepatic lobes as well as subcutaneous
thorax to produce trifocal models, i.e., twoHTs and one ST in each rat.
Tumor growth was followed with MRI every 2 days from 1 week after
the implantation.
Experimental Protocol
The experiment began when tumors reached a diameter of 0.7
to 1.2 mm at 14 days after implantation. These rats received either
intravenous (iv) injection of CA4P at a dose of 5 mg/kg (n = 6) or
equal volume of the solvent as vehicle controls (n = 6). All rats were
in vivo examined by MRI at 30 minutes before and 4, 24, and
48 hours after the injection. Rats were killed immediately after the
last MRI session for postmortem microangiography and histopathol-
ogy (Figure 1). The derived parameters reflecting therapeutic responses
were compared interindividually and intraindividually among tumors
at different time points.
Magnetic Resonance Imaging
A clinical 1.5-T whole-body MRI magnet (Symphony; Siemens,
Erlangen, Germany) with a maximum gradient capability of 30 mT/m
was used. Scanning was performed using a four-channel phased array
human wrist coil (MRI Devices, Waukesha, WI). As described else-
where [31], the rat was gas-anesthetized using a mask connected via
a polyethylene tube to a Harvard Apparatus System (Hollistoon, MA)
outside the MRI suite. During imaging, the anesthesia was main-
tained with inhalation of 2% isoflurane in the mixture of 20% oxygen
and 80% room air. The rat was placed supinely in a plastic holder
inside the coil with the penile vein cannulated for contrast agent and
drug administration.
Figure 1. Flow chart of experimental protocol; n, number of animals;
t, number of tumors.
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After axial, coronal, and sagittal scout images for localization,
T2-weighted imaging (T2WI), T1-weighted imaging (T1WI), diffusion-
weighted imaging (DWI), and contrast-enhanced T1WI (CE-T1WI)
were acquired in a transverse plane in all rats with slice thickness of
2.0 mm and a gap of 0.4 mm. For the DWI, diffusion gradients were
applied with 10 different b values (0, 50, 100,150, 200, 250, 300, 500,
750, and 1000 s/mm2) in three dimensions (x, y, and z) and averaged
for the calculation of the isotropic apparent diffusion coefficient (ADC)
values. A parallel imaging technique was applied with an acceleration
factor of 2 to reduce susceptibility artifacts and examination times [24].
For CE-T1WI, gadolinium-based contrast agent Gd-DOTA (Dotarem,
Guerbet, France) at a dose of 0.2 mmol/kg was administrated 1 minute
in advance. The acquisition parameters for all imaging sequences are
given in Table 1.
MRI Analyses
Image analyses were conducted using the built-in software on the
Siemens workstation to obtain the following measurements. All mea-
surable parameters were acquired by the three authors with consensus.
Tumor volume. T1WI, T2WI, and CE-T1WI were used as the
routine sequences to determine the tumor volume, location, and area
of necrosis. Tumor area was contoured manually on each slice of
T2WI. Tumor volume was calculated using the equation: tumor
volume = ∑[tumor area on each slice × (slice thickness + gap)]. Tumor
volume doubling time (DT) was calculated as described elsewhere
[36] using the following equation: DT = (t2 − t1) × ln2/ln (V2/V1),
where t2 − t1 indicates the length of time between two measurements,
and V2 and V1 denote the tumor volume measured at two points.
Tumor necrosis ratio. Central nonenhancing area on CE-T1WI is
considered necrosis. Necrosis volume was calculated the same way as
tumor volume. Necrosis ratio was defined as the volume of necrosis
over that of the entire tumor volume.
Calculation of ADC and normalization of signal intensity.
ADC values were calculated from DWI by using the following
monoexponential equation: S i = S0exp(−biADC) [29,37], where S i
is the signal intensity (SI) measured on the ith b value image, bi is the
corresponding b value, and S 0 is a variable that estimates the intrin-
sic SI (for b = 0 s/mm2). The percentile change in ADC at different
time points after treatment was defined by the equation (ADCpost −
ADCbaseline)/ADCbaseline × 100 to quantify therapy-related changes.
The measured SI was corrected with the phantoms from baseline
images as a standard reference. A region of interest (ROI) of 200 pixels
was placed on each phantom, and the SIs derived from two phantoms
were averaged as a standard value. The following formula was used to
normalize SI of each image: SIcorrected = SImeasured × (SIphantom measured/
SIphantom standard). By comparing to the liver parenchyma, the SI of
tumor was defined as hypointense, isointense, or hyperintense.
Tumor enhancement ratio. The tumor was delineated with an
operator-defined ROI on three central tumor-containing image slices,
and the average tumor SI was automatically generated on CE-T1WIs.
Enhancement ratio (ER) of SI was calculated to compare the degrees of SI
enhancement at different time points after the injection of Gd-DOTA.
The following formula was used: ER = (SIpostCA4P − SIbaseline)/SIbaseline ×
100%, where ER is the enhancement ratio between the SI enhancement
post-CA4P relative to that at the baseline, and SIpostCA4P and SIbaseline are
the SIs measured on post-CA4P and baseline CE-T1Wis, respectively.
Digital Microangiography and Vessel Density Quantification
Immediately after MRI sessions, rats were first heparinized with an
iv bolus of 500 U/kg and then killed with an overdose of pentobarbital
intraperitoneally. With a neck skin incision, the right carotid artery and
jugular vein were cannulated and the blood pool was flushed with 50 ml
of 5% glucose in normal saline. Barium sulfate suspension of 10 ml was
injected via the carotid catheter and the efflux was drained via jugular
vein. The rats were then radiographed with a digital mammography unit
(Em-brace; Agfa-Gevaert, Mortsel, Belgium) at 35 kV and 16 mAs. All
tumors were then excised and fixed in 10% formalin for 48 hours. The
fixed tumors were radiographed and then sliced into 3-mm sections in
the plane similar to the axial MR images using a Plexiglas matrix (Agar
Scientific, Essex, England), and the sections were radiographed again for
quantifications of vessel density.
Digitized photographs from microangiography were analyzed using
the ImageJ software for quantification of relative vessel density. Tumor
areas in radiographic imaging were contoured as ROIs in all tumor-
containing sections. As an index of vascular density, the mean gray val-
ues generated from the ImageJ software were compared between HTs
and STs from CA4P-treated rats and from vehicle controls as reference.
Hematoxylin and Eosin Staining and Histopathology
After microangiography, all tumor sections were paraffin embedded
and sliced into 10 μm using a microtome. The slides were then stained
with hematoxylin and eosin (H&E) formicroscopic assessment (Axioskop;
Zeiss, Oberkochen, Germany) with ×50 to ×400 magnifications. His-
tologic findings were further co-localized with the corresponding MRI
and microangiographic images for mutual verifications.
Statistical Analysis
Numerical data were expressed as means ± SD. Statistical analysis
was performed using SPSS (version 18.0, Chicago, IL). Tumor volume,
necrosis over tumor ratios, SIs, and vascular density among tumors in
different locations were compared using one-way analysis of variance.
A significant difference was considered for P < .05.
Results
General Aspects
All rats survived the anesthesia, tumor implantation and growth, and
MRI sessions and tolerated well with iv drug administrations. Trifocal
Table 1. Parameters for MRI Sequences.
T1WI T2WI DWI CE-T1WI
Sequence type TSE TSE EPI TSE
Repetition time 535 3810 1900 535
Echo time 9.2 106 95 9.2
Flip angle (degrees) 180 160 – 180
Turbo/EPI factor 7 19 91 7
Field of view (mm2) 50 × 140 50 × 140 58.3 × 162 50 × 140
Imaging acquisition matrix 100 × 256 100 × 256 81 × 192 100 × 256
In-plane resolution (mm2) 0.5 × 0.5 0.5 × 0.5 1.0 × 0.8 0.5 × 0.5
Slice thickness (mm) 2 2 2.4 2
Number of averages 4 3 6 4
Total acquisition time(s) 84 85 326 84
TSE, turbo spin echo; EPI, echo-planar imaging.
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tumors including two HTs in the right and left liver lobes and one ST
at subcutaneous thorax were successfully induced in all 12 rats, result-
ing in a sample size of 36 R1 tumors in total.
MRI Findings
All HTs were hypointense on T1WIs but hyperintense on T2WIs
at all time points. On CE-T1WIs, all HTs appeared hyperenhanced
at baseline in CA4P-treated group and at all time points in vehicle
control group. R1 tumors in the left and right hepatic lobes showed
almost identical MRI outlooks in the same group of rats. In all HTs
of CA4P-treated group only, a central signal void was surrounded by
a hyperenhanced rim on CE-T1WIs at 4 hours, and particularly at
24 and 48 hours after therapy, suggesting CA4P-induced vascular
shutdown and subsequent intratumoral necrosis. However, all STs
showed similar MRI behaviors in both groups, i.e., hypointense on
T1WIs, hyperintense on T2WIs, and hyperenhanced on CE-T1WIs
without being affected by CA4P injection (Figure 2). On DWI-
derived ADC maps, all tumors appeared somewhat hyperintense at
baseline. All tumors in vehicle control group showed ignorable changes
within 48 hours. However, in CA4P-treated rats, the HTs revealed
higher signal intensities in the central region at 4, 24, and 48 hours
(Figure 2), suggesting enhanced water diffusion due to tumorolysis re-
sulting from CA4P-induced ischemic necrosis. By contrast, the STs
showed slight signal increase only at 4 hours, likely due to CA4P-
induced reversible tumor tissue injury or edema that recovered spon-
taneously in 24 to 48 hours (Figure 2). Besides these visual findings,
a number of quantitative measurable parameters including tumor
volume, DT, tumor necrosis ratio, ADC, and ER were derived from
MRI to serve as imaging biomarkers for detecting therapeutic responses
as detailed below.
Tumor volume. The corresponding tumor volume growth curves
were shown in Figure 3A. Tumor volumes of the HTs and STs at
baseline were 0.84 ± 0.41 and 1.08 ± 0.43 cm3 and 0.96 ± 0.38 and
0.89 ± 0.49 cm3 in vehicle control and CA4P-treated group, respec-
tively, without significant differences (P > .05). In CA4P-treated rats,
the HTs presented a slower growth with the tumor volume of 0.88 ±
0.44, 0.95 ± 0.41, and 1.03 ± 0.45 cm3, in contrast to a rapid growth
of STs with the tumor volume of 1.24 ± 0.50, 1.53 ± 0.59, and 1.78 ±
0.66 cm3 at 4, 24, and 48 hours, respectively. Significant differences
(P < .05) were found between HTs and STs at 48 hours. However, in
vehicle control rats, both HTs and STs grew steadily (Figure 3A)
unlike the discrepancy seen with CA4P-treated group. Comparing
to vehicle control rats, CA4P-treated rats revealed a significant decline
in tumor volume growth only in the HTs (P < .01) but not in the STs
(P > .05) within 48 hours after injection (Figure 3A), suggesting di-
verse responses to CA4P between the HTs and the STs.
Tumor volume DT. As an index for tumor growth, tumor volume
DTs from baseline to 48 hours after CA4P were 8.3 ± 2.9 and 2.8 ±
0.6 days in HTs and STs, respectively, with a significant difference
(P < .01). Comparing to the vehicle control rats with a tumor DT of
2.6 ± 0.8 and 2.9 ± 0.9 days in the HTs and STs, respectively, a
significant difference (P < .001) was shown in DTs of HTs between
CA4P-treated and vehicle control rats, but DTs of STs revealed no
significant difference between the two groups. A distinctly prolonged
Figure 2. MRI findings in a rat with trifocal hepatic (HTs) and subcutaneous (ST) R1 tumors at baseline, 4, 24, and 48 hours after CA4P.
Relative to liver parenchyma, at all time points, the HTs (hollow arrows) and ST (solid arrow) all appeared hypointense on precontrast
T1WIs and hyperintense on T2WIs. On CE-T1WIs, although the HTs and ST were all hyperenhanced at baseline, only the ST could be
entirely enhanced at 4, 24, and 48 hours, with the HTs shown as unenhancedmasses surrounded by a hyperenhanced rim of SI increasing
with time, suggesting the presence of CA4P-induced necrosis only in HTs but not in the ST. On DWI-derived ADCmaps, all tumors shared
the same SI at baseline, suggesting intact tumor viability; however, after CA4P injection, the signal became stronger only in the HTs, sug-
gesting impaired tumor viability there but not in the ST.
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DT indicated a much slower growth of the HTs after CA4P injection;
meanwhile, the growth of STs remained unaffected by CA4P.
Tumor necrosis ratio. In vehicle control rats, CE-T1WI–derived
necrosis ratios remained constantly minimal in both HTs and STs within
48 hours (Figure 3B). In CA4P-treated rats, tumor necrosis ratio was
6.3 ± 3.4% and 5.3 ± 3.7% in HTs and STs, respectively, at baseline
without significant difference (P > .05). However, relative to the little
change with STs, a sharp increase of necrosis ratios to 78 ± 14%, 64 ±
14%, and 47 ± 10% at 4, 24, and 48 hours, respectively, occurred with
HTs (Figure 3B) due to CA4P-induced massive intratumoral necrosis.
Necrosis ratios in HTs gradually decreased with time as a result of tumor
regrowth at the periphery. Significant differences (P < .01) of necrosis
ratios were found between HTs and STs at all time points after CA4P.
Apparent diffusion coefficient. ADC values derived fromDWI served
as an imaging biomarker for tissue viability assessment (Figure 3C). All
tumors in vehicle control rats showed no ADC changes over 48 hours,
indicating virtually intact tumor viability. In CA4P-treated rats, sig-
nificant differences in ADC changes were found between HTs and
STs at 4, 24, and 48 hours after CA4P (P < .01). Comparing with ve-
hicle control rats, ADC changes in HTs increased significantly (P < .001)
after CA4P injection.
Enhancement ratio. CA4P-induced vascular shutdown caused a de-
crease of ER in HTs but a slight increase of ER in STs, with significant
differences (P < .01) between the HTs and STs at 4, 24, and 48 hours
after CA4P injection (Figure 3D). Comparing to the HTs in vehicle
control rats, the HTs in CA4P-treated rats demonstrated a significant
decrease of ER (P < .01) after injection, whereas the ERs of the STs
were comparable between the two groups (P > .05).
Digital Microangiography
Barium suspension served as an intravascular marker or contrast
agent for microangiography of the tumor vasculature. In CA4P-treated
rats, unlike the opacified vasculature of laterally located STs, the HTs
were hardly discernable on the whole-body microangiogram due to
superimposed bony structures and extratumoral vessels (Figure 4A).
However, on sectioned radiograph, intratumoral vasculature disappeared
centrally from the HTs with residual vessels existing only at periphery,
suggesting CA4P-induced vascular shutdown and intratumoral necro-
sis. STs showed both central and peripheral vessels, suggesting a lack
of response to CA4P. In vehicle control rats, both HTs and STs dis-
played intact tumor vasculature, which though appeared much denser
in HTs relative to STs (Figure 4B). Quantitatively, gray values mea-
sured on radiograph of tissue sections from HTs and STs were 121 ±
13.9 and 82.3 ± 10.6 in vehicle control rats and 54.5 ± 9.5 and 76.4 ±
11.2 in CA4P-treated rats, respectively. In vehicle control rats, vessel
density of HTs was significantly higher than that of STs (P < .01).
However, vessel density of HTs in CA4P-treated group was signifi-
cantly lower than that in vehicle controls (P < .001), whereas STs from
both groups were comparable in their vessel densities (P > .05),
Figure 3. Quantitative MRI-derived biomarkers in CA4P-treated and vehicle control groups (HTV, HTs from vehicle control rats; STV, STs
from vehicle control rats; HTC, HTs from CA4P-treated rats; STC, STs from CA4P-treated rats; *P < .05 in comparison with STC, HTV,
and STV at the same time point). (A) Line chart comparing tumor volumes at different time points. The HTs showed a delayed growth,
with the tumor volume significantly smaller than the STs at 48 hours after CA4P. (B) Bar chart shows the percentile of necrosis over
tumor ratios at different time points. Necrosis ratio of the HTs rose from less than 10% to about 80% at 4 hours and still remained about
50% 48 hours after CA4P. By contrast, little changes presented with the STs, similar to that of controls. (C) Bar chart of ADC percentile
changes relative to the baseline value shows a drastic increase in the HTs at 4, 24, and 48 hours after CA4P, relative to the negligible
changes in the STs and control animals. (D) Bar chart of percentile changes in ER relative to the baseline value derived from CE-T1WIs
shows drastically decreased values only with the HTs at 4, 24, and 48 hours after CA4P, relative to the slight changes in the STs and
control group.
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suggesting diverse responses to CA4P between HTs and STs and
consistent with the MRI and histologic findings.
Histologic Analysis and Correlation with MRI
Macroscopically on H&E-stained slides, intrahepatic and sub-
cutaneous rhabdomyosarcomas (R1) both appear as spherical solid
masses with clear borders to the surrounding normal tissues, but intra-
tumoral necrosis existed only with HTs, but not with STs, after the
CA4P treatment (Figure 5). Microscopically, while STs from both
groups remained viable with their patent vessels filled with injected
barium articles at the tumor core, HTs only from CA4P-treated group
demonstrated extensive central necrosis with a few layers of viable
tumor cells found adjacent to normal liver parenchyma (Figure 5).
The structures of blood vessels disappeared centrically only from the
CA4P-treated HTs, corresponding to a lack of central contrast en-
hancement on MRI (Figure 2) and a signal void from sectioned
microangiography in these tumors (Figure 4). Quantitatively, for
CA4P-treated HTs, tumor necrosis ratio obtained from microscopic
histomorphometry (0.63 ± 0.12) and from CE-T1WI (0.59 ± 0.13)
matched closely to each other (P > .05) with a statistically significant
linear correlation (R2 = 0.86, P < .001) as shown in Figure 6.
Discussion
In clinical patients, multiple growths of malignant neoplasm frequently
occur due to secondary spreading from one single primary focus to else-
where in the body. However, the majority of current studies on tumor
models are done with subcutaneous models for technical simplicity.
Animal models with tumors of the same origin but located in different
organs or tissues are therefore mandatory to simulate the widespread
metastasis in cancer patients. However, previous animal studies assessed
Figure 4. Digital microangiograms represent CA4P-treated group (A) and vehicle control group (B). (A) In CA4P-treated group, unlike the
opacified vasculature of laterally located STs (solid circle), the HTs (dashed circles) were hardly discernable on the whole-body micro-
angiogram due to superimposed bony structures and extratumoral vessels. However, on sectioned radiograph, intratumoral vasculature
disappeared centrally from the HTs with residual vessels existing only at periphery, suggesting CA4P-induced vascular shutdown and
intratumoral necrosis. The ST showed both central and peripheral vessels, suggesting a lack of response to CA4P, likely due to insuf-
ficient drug concentration. (B) In vehicle control rats, both HTs (dashed circles) and ST (solid circle) displayed intact tumor vasculature,
though the vasculature appeared much denser in the HTs relative to ST, suggesting the richer blood supply, hence higher drug con-
centration, in the former than the latter.
Figure 5. Gross andmicroscopic views of the H&E-stained sections
of the ST and HT sections from a CA4P-treated rat. (N, tumor necro-
sis; TV, tumor vessel; V, viable tumor tissues). Macroscopically
(upper row), both the ST (left) and HT (right) of rhabdomyosarcomas
(R1) appeared as spherical solid masses with clear borders to the
surrounding normal tissues. However, intratumoral necrosis existed
only with the HT, but not with the ST, suggesting their diverse re-
sponses to CA4P treatment. Microscopically (lower row), the ST
(left) remained viable with its intact vessels filled with injected bar-
ium articles at the tumor core. However, the HT (right) demonstrated
extensive central necrosis with a few layers of viable tumor cells
found adjacent to normal liver parenchyma, and the structures of
blood vessels disappeared centrically, corresponding to a lack of
central contrast enhancement on MRI (Figure 2) and a signal void
on sectioned microangiography (Figure 4).
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the therapeutic responses to CA4P in either STs [34] or HTs [38] but
not in both. Therefore, it was impossible to directly compare the
efficacy of the same drug at a given dose in tumors of different locations.
In this study, the rat model of multifocal R1 tumors allowed us to expose
and document the diverse responses to CA4P in the same individual
animals, which is deemed clinically relevant. This experimental setting
may prove useful for screening the efficacy of other anticancer drugs or
determining the adequate dosage of a certain drug in the subjects with
metastatic diseases.
MRI is currently the most versatile method for noninvasive assess-
ment of the responses to a therapy by malignant tumors [39–41]. This
is realized by a comprehensive array of MRI-derived parameters as
morphologic, physiological, and metabolic/molecular biomarkers for
detection, characterization, and therapeutic evaluation of malignancies
[13,42,43]. Besides the principal criteria of volume alteration or tumor
DT as tumor growth indices for evaluating tumor response to anti-
cancer therapies, such imaging biomarkers also include tumor necrosis
ratio, ADC, and ER for quantitative assessment of tumor burden and
therapeutic evaluation of tumor response after any anticancer treatment
in clinical oncology trials and animal experiments [13,38,42,43].
In the present study, within 48 hours after CA4P, STs grew much
faster in comparison with HTs, as reflected in the tumor volume curve
and the corresponding tumor DTs. The presence and absence of necro-
sis in HTs and STs were evidenced by the products of necrosis ratio
derived from CE-T1WIs, suggesting the diverse responses to CA4P
in tumors of the same cell line but different locations. Declined ER
in HTs reflected the impaired distribution of contrast agent in extra-
vascular and intravascular space of the tumor. A close linear correlation
of the necrosis ratios between CE-T1WI and the histopathology in
HTs confirms the reliability of such MRI biomarkers as viability indi-
ces. ADC obtained from DWI, which defines water molecular motion
in tissue and cellular environment, is elicited to characterize pathologic
alterations in tumors, i.e., the changes in ADC allows for the differen-
tiation of necrosis and edema from viable tissue [44]. Relative to the
unaltered ADC in all STs or HTs of vehicle controls, the significantly
elevated ADC in HTs of CA4P-treated rats indicated an increased
mobility of water molecules resulting from a decreased cellular density,
disintegrated cell membrane, and loss of cell viability.
Microangiography was applied as a postmortem gold standard
method to visualize and quantify tumor vascularity and CA4P-
induced intratumoral vascular shutdown [13,45,46]. The barium sus-
pension injected from the carotid artery was evenly filled in the entire
arterial system covering both HTs and STs under an equal pressure,
hence a more reliable comparison between tumors of different loca-
tions. In vehicle control rats, the higher and lower tumor vessel den-
sity demonstrated in HTs and STs, respectively, are understandable
in view of their host organs, i.e., hypervascular liver versus hypovas-
cular subcutis. Thus, HTs may be better facilitated to recruit the re-
leased angiogenic factors such as vascular endothelial growth factor,
angiopoietins, and epidermal growth factor for neoangiogenic process
of malignancies. Consequently, HTs with denser and immature
blood vessels can be more susceptible to CA4P treatment compared
to STs, as proven by the microangiographic outcomes.
The core issue related to the findings of this study is to extrapolate
why HTs and STs responded differently to CA4P. It is known that
response to chemotherapy is generally dose-dependent. Indeed, mas-
sive intratumoral necrosis was successfully induced in rats with STs
of the same R1 cell line by CA4P at a high dose of 25 mg/kg [47],
which is much higher than the maximum tolerate dose (MTD) of
68 mg/m2 as defined in clinical trials of CA4P for human cancer
patients [8]. The iv injected dose of CA4P at 5 mg/kg in this study
is closer to the MTD in humans and therefore more clinically rel-
evant [26]. However, this dose seems only high enough to exert
tumoricidal effect on HTs but not STs, most likely due to the distinct
intratumoral concentrations of the drug distributing through the
vasculatures of diverse density. The exact dose to adequately cause
therapeutic effect on both HTs and STs must fall into the range be-
tween 5 and 25 mg/kg and has to be further defined. Similarly, human
cancers of different locations may respond also differently to CA4P at
any dose lower than the MTD, which explains the overall unsatisfac-
tory clinical outcomes despite the over 30 years’ development of this
drug [1]. There seems to be a justified need to redefine the best clinical
dosage for CA4P that maximizes its anticancer effect but meanwhile
does not render any irreversible adverse effects on cancer patients. Be-
sides the above-mentioned vessel density–determined drug concentra-
tions as the most straightforward explanation, other plausible reasons
may include the following.
Upon iv injection, the discrepancy in responsiveness to CA4P
between HTs and STs can be attributed to the differences within
the inherent vessel structures, the microenvironmental components,
the host-tumor interactions, and the levels of gene expression of the
tumor, which may collectively affect tumor blood perfusion, diffu-
sion, and permeability [48], resulting in reduction in blood flow
and generation of hypoxia in different degrees depending on loca-
tions. Previous studies have demonstrated the presence of physiolog-
ical differences in vessel density, vessel diameters, permeability, and
leukocyte rolling between HTs and STs [49], which may lead to dif-
ferent degrees on tumor neoangiogenesis and microcirculation. Vari-
ation in heterogeneity of blood flow and vascular tortuousness within
liver or STs may affect the delivery of therapeutic agents to vascular
targets [13,49]. Meanwhile, dissimilar levels of gene expression have
been shown in tumors of the liver and subcutaneous site, indicating
the impact of microenvironment on genotypes and phenotypes of the
Figure 6. Linear correlation chart shows that tumor necrosis ratios
obtained from microscopic histomorphometry and from CE-T1WI
in CA4P-treated group matched closely to each other (P > .05) with
a statistically significant linear correlation (R2 = 0.86, P < .001). The
necrosis ratios were calculated on CE-T1WIs at 48 hours after
the injection of CA4P and on postmortem H&E-stained slides on a
tumor-by-tumor basis (n = 12). The changes of necrosis ratios de-
termined by in vivo MRI and ex vivo histopathology are negligible
in all the STs.
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tumors of the same origin [50]. For instance, expressions of certain
specific genes were significantly lower in HTs than in STs, whereas
down-regulation of these genes was associated with the higher degree
of malignancy [50]. All the above elements may lead to the more
immature vasculature in HTs compared to STs, leading to distinctly
higher susceptibility of HTs to CA4P, as have been demonstrated
in this study.
Study Limitations
Ktrans map was not used in this study for more robust validation
of the MRI data. Ktrans map as an important index from perfusion-
weighted MR image allows cross-site comparisons of hemodynamics.
Characterization of hemodynamic differences between tumors of dif-
ferent sites may provide more valuable information for exploring the
different therapeutic responses to CA4P.
To our knowledge, this study is the first time that tumors of dif-
ferent sites in the same animal were implanted and were gotten into
the same imaging plane at approximate the same size, which allow
making a striking and direct comparison between the properties of
the tumors on MR images. Meanwhile, it is the first time that re-
sponses to CA4P were compared both interindividually and intra-
individually in a rat model bearing both HTs and STs of the same
origin. MRI and microangiography allowed quantitative documenta-
tion of the diverse therapeutic responses between tumors of different
locations, which are likely caused by different drug concentrations
due to distinct tumor vascularity and microenvironment. These find-
ings emphasize the presence of cancer heterogeneity and the impor-
tance of individualization of drug delivery.
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